Metabolic launches study to test continuous glucose monitors in type 2 diabetes patients

A Dubai clinic best known for treating metabolic conditions is launching a three-month study to measure how well continuous glucose monitors work for people with type 2 diabetes. Metabolic, the tech-enabled health platform formerly known as GluCare.Health, announced the study in partnership with Dexcom, whose G7 sensor will be used across the trial.

The study will track whether wearing a CGM device improves HbA1c levels and other key blood sugar metrics in patients enrolled in Metabolic's care program. Every participant will receive a Dexcom G7 sensor free of charge for the full three months, so cost does not stop anyone from taking part.

This is the 51st study Metabolic has published or initiated, and it adds to a research track record that has seen the clinic chosen to support launches of major drugs including Mounjaro, Foundayo, and the Wegovy pill.

How will it work?

The study is formally titled 'Evaluation of Continuous Glucose Monitoring on Glycemic Control and Diabetes Management in Type 2 Diabetes Patients.' It is a prospective observational study, meaning researchers will follow patients forward in time rather than looking back at existing records.

Participants are adults with type 2 diabetes drawn from Metabolic's existing patient base. The setup is straightforward:

• Each participant wears the Dexcom G7 sensor throughout the study period
• Metabolic's clinical team monitors real-time glucose data alongside standard care
• Researchers measure changes in HbA1c and CGM-specific metrics over three months
• All sensors are provided at no cost to remove financial barriers

Dr. Ihsan Almarzooqi, Co-Founder and Managing Director of Metabolic, said: 'Continuous glucose monitoring is one of the most powerful tools available for understanding a patient's metabolic reality in real time. This study will give us robust evidence for the role of CGM within a structured T2D care programme, and we expect the findings to meaningfully inform how we deploy this technology at scale.'

Why does it matter?

Type 2 diabetes is a major public health problem in the UAE. By some estimates, up to 70% of people with the condition in the country have poorly controlled blood sugar, which raises the risk of serious complications including kidney disease, nerve damage, and cardiovascular problems.

CGM technology is already well-established for type 1 diabetes, where it has strong clinical backing. The picture for type 2 diabetes is less clear, particularly in structured, high-engagement care programs of the kind Metabolic runs. Real-world data from the Gulf region is especially thin.

If the study shows that CGM use improves outcomes in this setting, it could make a case for broader insurance coverage and clinical adoption across the region, where uptake remains low compared to Western markets.

The context

Metabolic sits at the intersection of two fast-moving areas: digital health platforms and GLP-1 drug adoption. The clinic has been involved in launches of some of the most talked-about weight and metabolic treatments of the past few years, which gives it both a large patient base and credibility with device and drug makers looking for research partners.

Dexcom, for its part, has been working to expand CGM use beyond type 1 diabetes for several years. The G7 is its latest-generation sensor, smaller and faster to set up than previous models. Getting real-world evidence from a structured clinic like Metabolic fits Dexcom's strategy of building the case for broader CGM adoption in type 2 diabetes globally.

Metabolic holds accreditations from the International Consortium of Health Outcome Measures (ICHOM), the College of American Pathologists (CAP), and Joint Commission International (JCI). More information is available at metabolic.health.